Disclosures
GLP-I receptor agonists—including semaglutide, liraglutide, dulaglutide, and tirzepatide—have been prescribed (on-and-off label) for weight management, including obesity, along with a reduced caloric diet and increased physical activity. Take precaution with, and read all warnings concerning, GLP-1s, as they may cause serious side effects, including a risk of thyroid c-cell tumors. Do not use if you or your family have a history of a type of thyroid cancer called MTC (medullary thyroid carcinoma) or MEN 2 (multiple endocrine neoplasia syndrome).

Regulations serve as a safeguard, ensuring that compounded medications are prepared safely and effectively. Compounding pharmacies adhere to guidelines set by regulatory bodies, such as the Food and Drug Administration (FDA) in the United States. These regulations govern various aspects of compounding, including the use of specific ingredients, labeling requirements, and documentation.